BriaCell Appoints Martin Schmieg to Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, Dec. 1, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously …

BRIACELL THERAPEUTICS CORP. CLOSES DEBT FINANCING

BERKELEY, Calif., and VANCOUVER, British Columbia, November 17, 2020 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed a brokered private placement (the “Offering”) of an unsecured convertible debenture unit of the Company (the …

BriaCell Announces Collaboration with the National Cancer Institute

• BriaCell and National Cancer Institute to collaborate on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to …

BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months

• Overall Survival of 13.3 months in patients, including 14 months in patients with Grade I/II tumors, suggesting clinical benefit; • Comparison: 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting without BriaCell’s treatment; • Additional overall survival data will be presented at the 2020 San Antonio Breast Cancer Symposium®, …

BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11

• Clinical and pathological findings to be presented from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted …

Note from BriaCell Management – October is Breast Cancer Awareness Month

BERKELEY, Calif., and VANCOUVER, British Columbia, October 1, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer …

BriaCell to Present at the 3rd Annual Biologics World Nordic 2020

BERKELEY, Calif., and VANCOUVER, British Columbia, September 15, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that Dr. Bill Williams, BriaCell’s President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual …

BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation

BERKELEY, Calif., and VANCOUVER, British Columbia, September 4, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that it has received a research grant from the Wiseman Cancer Research Foundation, a 501c(3) nonprofit organization based in Beverly Hills, CA. …

BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance

BERKELEY, Calif., and VANCOUVER, British Columbia, August 17, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that further to its news release dated August 11, 2020, it has received the approval of the TSX Venture Exchange for the shares …

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, in combination with pembrolizumab (KEYTRUDA®; manufactured by …